① J.P. Morgan covered Schudi Biotech for the first time in a report released on Tuesday, giving it an “overfit” rating, with a target price of $65 per share; ② Analyst Hardik Parikh pointed out that the drug is an oral pill, not an injection, and may have a slight advantage in terms of time to market.
Financial Services Association, May 23 (Editor: Zhao Hao) Analysts at J.P. Morgan Chase, a well-known American investment bank, have predicted that the annual sales of the global GLP-1 drug market will exceed 100 billion US dollars by 2030.
This size means it may be difficult for the two industry leaders, Eli Lilly and Novo Nordisk, to completely divide this market, leaving plenty of room for more companies to enter the field and seize shares. Meanwhile, Xiaomo recently stated that Structure Therapeutics (Structure Therapeutics) is a name investors should pay attention to.
J.P. Morgan covered Schudi Bio for the first time in a report released on Tuesday (May 21), giving it an “Overrated” (Overrated) rating, with a target price of $65 per share. As of press release, Shuodi Biotech, which is currently trading, rose more than 6% to $38, and Komo believes it still has an increase of at least 70%.
According to information, Schudi Biotech, headquartered in California, is a clinical-stage biopharmaceutical company dedicated to developing novel oral treatments for various chronic diseases and addressing unmet medical needs.
Using a cutting-edge technology platform built on structure-based drug discovery and computational chemistry, Schudi Biotech researches and develops various oral small molecule therapeutics for the treatment of metabolic, cardiovascular, and pulmonary diseases.
In February of last year, Schudi Biotech was listed on the NASDAQ exchange under the stock code “GPCR”. Currently, the market capitalization exceeds 1.7 billion US dollars, and it is a relatively low-key presence in the financial world.
Shuodi Biotech is developing an oral GLP-1 receptor small molecule agonist “GSBR-1290,” which is a proven pharmaceutical target for the treatment of type 2 diabetes and obesity. Xiaomo said it saw a “meaningful” upward space for Schudi Biotherapy.
Komo analyst Hardik Parikh pointed out that the drug is an oral pill, not an injection, and may have a slight advantage in terms of time to market. It is one to two years ahead of most competitors and only behind Eli Lilly's orforglipron.
Eli Lilly's orforglipron is expected to go public in 2026, while Schudi Biotech's competitor is likely to go on sale in 2029.
According to Komo, early results showed that GSBR-1290 “has no major concerns” in terms of safety and can provide patients with “uniform” weight loss results. In comparison, Pfizer's competitor “danuglipron” had a high incidence of adverse side effects, which caused Pfizer to stop developing the drug.
Parikh wrote, “We believe that over time, Schoodi Biotech can gain close to a 5% share in the oral market, and GSBR-1290 may be an attractive partnership opportunity for large biopharmaceutical companies that want to participate in the market.”